Page last updated: 2024-11-07

gw420867x

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

GW420867X: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID154048
CHEMBL ID301370
SCHEMBL ID464732
MeSH IDM0354366

Synonyms (31)

Synonym
hby1293
propan-2-yl (2s)-2-ethyl-7-fluoro-3-oxo-1,2,3,4-tetrahydroquinoxaline-1-carboxylate
bdbm2955
opaviraline
hby-1293
gw-420867x
isopropyl (2s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydroquinoxaline-1(2h)-carboxylate
HBQ ,
hby1293/gw867
s-3-ethyl-6-fluoro-4-isopropoxycarbonyl-3,4-dihydro-quinoxalin-2(1h)-one
gw 867x
isopropyl (2s)-2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate
gw420867x
gw867
DB07884
CHEMBL301370
gw-420867
propan-2-yl (2s)-2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate
178040-94-3
unii-q3a8eu2nmu
isopropyl (s)-2-ethyl-7-fluoro-3,4-dihydro-3-oxo-1(2h)-quinoxalinecarboxylate
opaviraline [inn]
q3a8eu2nmu ,
SCHEMBL464732
DTXSID60170415
AKOS027326866
1-methylethyl (2s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydroquinoxaline-1(2h)-carboxylate
isopropyl (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydroquinoxaline-1(2h)-carboxylate
isopropyl (s)-2-ethyl-7-fluoro-3,4-dihydro-3-oxoquinoxalin-1(2h)-carboxylate
Q27097092
1(2h)-quinoxalinecarboxylic acid,2-ethyl-7-fluoro-3,4-dihydro-3-oxo-,1-methylethyl ester,(2s)-

Research Excerpts

Overview

GW420867X is a nonnucleoside inhibitor of HIV-1 reverse transcriptase.

ExcerptReferenceRelevance
"GW420867X is a nonnucleoside inhibitor of HIV-1 reverse transcriptase. "( GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine.
Arasteh, K; Burt, V; Cass, L; Dallow, N; Jones, A; Kleim, JP; Klein, A; Moore, KH; Müller, M; Prince, W; Wood, R,
)
3.02

Effects

ExcerptReferenceRelevance
"GW420867X has few contacts with Tyr188, hence, explaining the small effect of mutating this residue on inhibitor-binding potency."( Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.
Chamberlain, PP; Chan, JH; Kleim, JP; Nichols, CE; Ren, J; Short, SA; Stammers, DK; Weaver, KL, 2007
)
1.29

Toxicity

ExcerptReferenceRelevance
" Adverse effects reported by subjects on the active drug were similar to those receiving placebo."( Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Boyce, M; Cass, LM; Dallow, N; Hardman, TC; Jones, A; Moore, KH; Prince, WT,
)
0.36

Pharmacokinetics

The pharmacokinetic findings of this study imply that systemic exposure to GW420867X decreases with increasing dose and displays time-variant pharmacokinetics. This suggests decreased absorption and/or increased clearance of GW4 20867X.

ExcerptReferenceRelevance
" Time to Cmax (tmax) increased from a median value of 1 h following the 10-mg dose, to 3 h after the 200-mg dose."( Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Boyce, M; Cass, LM; Dallow, N; Hardman, TC; Jones, A; Moore, KH; Prince, WT,
)
0.36
"The pharmacokinetic findings of this study imply that systemic exposure to GW420867X decreases with increasing dose and displays time-variant pharmacokinetics, which suggests decreased absorption and/or increased clearance of GW420867X."( Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Boyce, M; Cass, LM; Dallow, N; Hardman, TC; Jones, A; Moore, KH; Prince, WT,
)
0.59
" Following single-dose administration, GW420867X was readily absorbed with a median time to peak concentration of 3 to 5 hours."( Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
Boyce, M; Cass, LM; Dallow, N; Hardman, TC; Jones, A; Moore, KH; Prince, WT, 2001
)
0.85
" We performed population pharmacokinetic analysis on three different doses of GW 420867X (50, 100, and 200 mg)."( Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation.
Bye, A; Drusano, GL; Kleim, JP; Moore, KH; Prince, W, 2002
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
"GW420867X was well tolerated and has potent antiretroviral activity alone and in combination with 3TC plus ZDV."( GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine.
Arasteh, K; Burt, V; Cass, L; Dallow, N; Jones, A; Kleim, JP; Klein, A; Moore, KH; Müller, M; Prince, W; Wood, R,
)
3.02

Bioavailability

ExcerptReferenceRelevance
"The effect of food on the bioavailability of GW420867X, a novel nonnucleoside reverse transcriptase inhibitor, was investigated in 15 young, healthy, male volunteers."( The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers.
Cass, LM; Dallow, NS; Jones, AE; Moore, KH; Prince, WT; Sisson, JR, 2001
)
0.8

Dosage Studied

ExcerptRelevanceReference
"8 (200 mg) after 14 days of dosing compared to the corresponding single dose."( Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Boyce, M; Cass, LM; Dallow, N; Hardman, TC; Jones, A; Moore, KH; Prince, WT,
)
0.36
" The terminal elimination t(1/2) was 50 hours, which supports once-daily dosing in future studies."( Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
Boyce, M; Cass, LM; Dallow, N; Hardman, TC; Jones, A; Moore, KH; Prince, WT, 2001
)
0.58
" The area under the curve over the dosing interval (AUCtau)on day 14 increased less than proportionally to dose, suggesting there was increased clearance and/or decreased absorption."( GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine.
Arasteh, K; Burt, V; Cass, L; Dallow, N; Jones, A; Kleim, JP; Klein, A; Moore, KH; Müller, M; Prince, W; Wood, R,
)
1.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.17900.00060.91418.3200AID1795437
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.11200.00011.076810.0000AID1272056; AID198385
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Activity0.02900.00091.30738.0000AID199980
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC90 (µMol)0.00790.00170.03850.3100AID1272056; AID198577
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID198577Inhibitory concentration for 90% inhibition of HIV-1 reverse transcriptase, whole cell based antiviral assay2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.
AID199980Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT)2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1272056Inhibition of HIV1 reverse transcriptase2016European journal of medicinal chemistry, Jan-27, Volume: 108Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
AID198385Inhibitory concentration for 50% inhibition of HIV-1 reverse transcriptase2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1795437HIV-1 RT Assay from Article 10.1016/s0960-894x(00)00321-8: \\Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.\\2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (6.67)18.2507
2000's12 (80.00)29.6817
2010's2 (13.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (29.41%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (64.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]